AN OPEN-LABEL MULTICENTER PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AB-3028 IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Prostate
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male
  • Other Inclusion Criteria:
    In order to participate in this study, you must met the following conditions:
    1. At least 18 years of age at time of signing informed consent form
    2. Prior prostate cancer treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy (e.g. abiraterone acetate, apalutamide, enzalutamide, darolutamide)
    3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

You may not be eligible for this study if the following are true:

  • You will not be able to participate in this study if any of the following apply:
    1. Any prior systemic therapy for CRPC within 14 days prior to scheduled protocol required leukapheresis, except for maintenance hormonal therapy (e.g., gonadotropin releasing hormone agonist)
    2. Central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression
    3. Subjects who received prior cellular therapy and experienced cellular therapy-related Grade 4 CRS or neurotoxicity, even if fully recovered



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.